Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment

December 15, 2015
William Sikov, MD

Special Reports, Breast Cancer (Issue 2), Volume 1, Issue 2

William Sikov, MD, associate director of Clinical Research, Program in Women

William Sikov, MD, associate director of Clinical Research, Program in Women’s Oncology, Women and Infants Hospital of Rhode Island, on the phase II CALGB 40603 trial, which tested if standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab would result in a pathologic complete response in patients with stage II/III triple-negative breast cancer.